Protalix BioTherapeutics Inc. (DE) Common Stock (PLX)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of confusing a low multiple with a bargain. Protalix is a small biopharma with approved rare-disease products, Elelyso and Elfabrio, and a plant-cell protein platform plus PRX-115 in Phase 2. That gives it some regulatory and technical barriers, but the record shows no wide moat: revenue was $65.5 million in FY2023, $53.4 million in FY2024, and $52.7 million in FY2025, while net income went from $8.3 million to $2.9 million to a $6.6 million loss, or EPS -$0.08. The latest quarters are better: in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $33.8 million and net income $18.3 million, EPS $0.22; in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $19.9 million and net income $3.8 million, EPS $0.05. Still, the swing is large. The balance sheet has low leverage, D/E 0.13, and trailing free cash flow is $7.7 million, a 3.5% FCF yield. At the 2026-10-13 close of $2.75, FairStock calculates P/E 11.96, P/B 3.09, EV/EBITDA 7.74, PEG 0.01, Graham Number $2.15, and margin of safety -27.91%. Piotroski 2/9, Altman Z -0.21, and FairStock Score 27/100 argue caution. FairStock also classifies it as TURNAROUND, with a loss in the latest year after earlier profits. I see a speculative, lumpy business, not a clear value bargain.

In plain English: Protalix makes medicines for rare diseases, including Gaucher and Fabry disease treatments, and is developing another medicine. The business has been uneven: it lost money in its latest full year but has made money in recent quarters, and it has low debt. At $2.75, the stock looks more expensive than what its earnings and book value alone would suggest, so it is not obviously a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer